RESUMO
Combined treatment of murine leukemia P388 with doxorubicin and platinum(IV)-nitroxyl complex ÐС118 administered in low doses improved efficiency of treatment (cure of 83% of animals) without increasing toxicity.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Citostáticos/farmacologia , Doxorrubicina/farmacologia , Leucemia P388/tratamento farmacológico , Compostos Organoplatínicos/farmacologia , Animais , Esquema de Medicação , Leucemia P388/mortalidade , Leucemia P388/patologia , Longevidade/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos DBA , Análise de SobrevidaRESUMO
In experimental animals with tumors it was studied antitumor activity of spirocyclic hydroxamic acids which could be classified as targeted agents as their target was enzyme histonedeacetylase, which was involved in the neoplastic process. The results showed that the hydroxamic acids were chemosensitizers for anticancer agents increasing their efficacy and enabling the researchers to reduce significantly the therapeutic dose. Also it was showed that hydroxamic acid, containing nitrogen mustard, was effective in the action on tumors with phenotype and genotype of multidrug resistance.